Meeting Coverage:

American Society of Cataract and Refractive Surgery Meeting

ASCRS: 2015

Maintaining Visual Performance with Topical Cyclosporine Therapy in Patients with Dry Eye: the IMPACT Study

Show Description +

Moderator Mark Kontos, MD, of Empire Eye in Spokane, Washington, and Karl Stonecipher, MD, of TLC Laser Eye Centers in Greensboro, North Carolina, discuss the results of the IMPACT study. Cataract patients with significant dry eye disease were treated with Restasis and their visual symptoms and objective findings were evaluated over 6 months.

Posted: 4/16/2015

Keywords:

cyclosporine

Dry Eye

Up Next


The Ethics of Femtosecond Laser Cataract Surgery

Kendall Donaldson, MD, Mark Kontos, MD

The Refractive Surgery Alliance

Guy M. Kezirian, MD, Jay S. Pepose, MD, PhD

First-ever Iris Prosthesis Skills Lab at ASCRS

Michael Snyder MD, Steven Vold, MD

Corneal Topographic Astigmatism and Total Corneal Power

Noel Alpins, FRANZCO, FRCOphth, Steven Vold, MD

Advanced Ocular Modeling for IOL Power Calculations

Arthur Cummings, MD, Michael Mrochen, PhD

Preview to the 2015 Cataract and Refractive Surgery Meeting in San Diego

Cynthia Matossian, MD, Damien Goldberg, MD, George O. Waring IV, MD, James Katz, MD, Robert J. Weinstock, MD, William Trattler, MD

What's New in the Treatment of Bacterial Keratitis?

Casey Claypool, OD, Francis Mah, MD

Cross-Linking: Use in Refractive Surgery

Arthur Cummings, MD, Michael Mrochen, PhD

Maintaining Visual Performance with Topical Cyclosporine Therapy in Patients with Dry Eye: the IMPACT Study

Moderator Mark Kontos, MD, of Empire Eye in Spokane, Washington, and Karl Stonecipher, MD, of TLC Laser Eye Centers in Greensboro, North Carolina, discuss the results of the IMPACT study. Cataract patients with significant dry eye disease were treated with Restasis and their visual symptoms and objective findings were evaluated over 6 months.

Posted: 4/16/2015

Keywords:

cyclosporine

Dry Eye

Please log in to leave a comment.

More From ASCRS: 2015 Coverage